{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T23:04:04Z","timestamp":1779145444270,"version":"3.51.4"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2024,6,26]],"date-time":"2024-06-26T00:00:00Z","timestamp":1719360000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,6,26]],"date-time":"2024-06-26T00:00:00Z","timestamp":1719360000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100002347","name":"Bundesministerium f\u00fcr Bildung und Forschung","doi-asserted-by":"publisher","award":["FKZ: 01KX2121"],"award-info":[{"award-number":["FKZ: 01KX2121"]}],"id":[{"id":"10.13039\/501100002347","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002347","name":"Bundesministerium f\u00fcr Bildung und Forschung","doi-asserted-by":"publisher","award":["FKZ: 01KX2121"],"award-info":[{"award-number":["FKZ: 01KX2121"]}],"id":[{"id":"10.13039\/501100002347","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002347","name":"Bundesministerium f\u00fcr Bildung und Forschung","doi-asserted-by":"publisher","award":["FKZ: 01KX2121"],"award-info":[{"award-number":["FKZ: 01KX2121"]}],"id":[{"id":"10.13039\/501100002347","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002347","name":"Bundesministerium f\u00fcr Bildung und Forschung","doi-asserted-by":"publisher","award":["FKZ: 01KX2121"],"award-info":[{"award-number":["FKZ: 01KX2121"]}],"id":[{"id":"10.13039\/501100002347","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002347","name":"Bundesministerium f\u00fcr Bildung und Forschung","doi-asserted-by":"publisher","award":["FKZ: 01KX2121"],"award-info":[{"award-number":["FKZ: 01KX2121"]}],"id":[{"id":"10.13039\/501100002347","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002347","name":"Bundesministerium f\u00fcr Bildung und Forschung","doi-asserted-by":"publisher","award":["FKZ: 01KX2121"],"award-info":[{"award-number":["FKZ: 01KX2121"]}],"id":[{"id":"10.13039\/501100002347","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002347","name":"Bundesministerium f\u00fcr Bildung und Forschung","doi-asserted-by":"publisher","award":["FKZ: 01KX2121"],"award-info":[{"award-number":["FKZ: 01KX2121"]}],"id":[{"id":"10.13039\/501100002347","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100017590","name":"Universit\u00e4tsklinikum Essen","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100017590","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Digit Imaging. Inform. med."],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Standardized reporting of multiparametric prostate MRI (mpMRI) is widespread and follows international standards (Pi-RADS). However, quantitative measurements from mpMRI are not widely comparable. Although T2 mapping sequences can provide repeatable quantitative image measurements and extract reliable imaging biomarkers from mpMRI, they are often time-consuming. We therefore investigated the value of quantitative measurements on a highly accelerated T2 mapping sequence, in order to establish a threshold to differentiate benign from malignant lesions. For this purpose, we evaluated a novel, highly accelerated T2 mapping research sequence that enables high-resolution image acquisition with short acquisition times in everyday clinical practice. In this retrospective single-center study, we included 54 patients with clinically indicated MRI of the prostate and biopsy-confirmed carcinoma (n\u2009=\u200937) or exclusion of carcinoma (n\u2009=\u200917). All patients had received a standard of care biopsy of the prostate, results of which were used to confirm or exclude presence of malignant lesions. We used the linear mixed-effects model-fit by REML to determine the difference between mean values of cancerous tissue and healthy tissue. We found good differentiation between malignant lesions and normal appearing tissue in the peripheral zone based on the mean T2 value. Specifically, the mean T2 value for tissue without malignant lesions was (151.7\u00a0ms [95% CI: 146.9\u2013156.5\u00a0ms] compared to 80.9\u00a0ms for malignant lesions [95% CI: 67.9\u201379.1\u00a0ms]; p\u2009&lt;\u20090.001). Based on this assessment, a limit of 109.2\u00a0ms is suggested. Aditionally, a significant correlation was observed between T2 values of the peripheral zone and PI-RADS scores (p\u2009=\u20090.0194). However, no correlation was found between the Gleason Score and the T2 relaxation time. Using REML, we found a difference of -82.7\u00a0ms in mean values between cancerous tissue and healthy tissue. We established a cut-off-value of 109.2\u00a0ms to accurately differentiate between malignant and non-malignant prostate regions. The addition of T2 mapping sequences to routine imaging could benefit automated lesion detection and facilitate contrast-free multiparametric MRI of the prostate.<\/jats:p>","DOI":"10.1007\/s10278-024-01150-6","type":"journal-article","created":{"date-parts":[[2024,6,26]],"date-time":"2024-06-26T18:14:53Z","timestamp":1719425693000},"page":"3304-3315","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Value of MRI - T2 Mapping to Differentiate Clinically Significant Prostate Cancer"],"prefix":"10.1007","volume":"37","author":[{"given":"Andreas Michael","family":"Bucher","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9194-5955","authenticated-orcid":false,"given":"Jan","family":"Egger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julia","family":"Dietz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ralph","family":"Strecker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tom","family":"Hilbert","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eric","family":"Frodl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mike","family":"Wenzel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tobias","family":"Penzkofer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bernd","family":"Hamm","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Felix KH","family":"Chun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"Vogl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jens","family":"Kleesiek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martin","family":"Beeres","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,6,26]]},"reference":[{"issue":"6","key":"1150_CR1","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1016\/j.euo.2021.09.006","volume":"4","author":"G Gandaglia","year":"2021","unstructured":"Gandaglia G, Leni R, Bray F, et al. Epidemiology and prevention of prostate cancer. Eur Urol Oncol. 2021;4(6):877-892. https:\/\/doi.org\/10.1016\/j.euo.2021.09.006","journal-title":"Eur Urol Oncol."},{"issue":"6","key":"1150_CR2","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1053\/j.semnuclmed.2016.07.002","volume":"46","author":"M Nguyen-Nielsen","year":"2016","unstructured":"Nguyen-Nielsen M, Borre M. Diagnostic and therapeutic strategies for prostate cancer. Semin Nucl Med. 2016;46(6):484-490. https:\/\/doi.org\/10.1053\/j.semnuclmed.2016.07.002","journal-title":"Semin Nucl Med."},{"issue":"3","key":"1150_CR3","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1097\/RLI.0000000000000520","volume":"54","author":"J Mai","year":"2019","unstructured":"Mai J, Abubrig M, Lehmann T, et al. T2 mapping in prostate cancer. Invest Radiol. 2019;54(3):146-152. https:\/\/doi.org\/10.1097\/RLI.0000000000000520","journal-title":"Invest Radiol."},{"issue":"5","key":"1150_CR4","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1016\/j.eururo.2022.07.025","volume":"82","author":"N Grivas","year":"2022","unstructured":"Grivas N, Lardas M, Espin\u00f3s EL, et al. Prostate Cancer Detection Percentages of Repeat Biopsy in Patients with Positive Multiparametric Magnetic Resonance Imaging (Prostate Imaging Reporting and Data System\/Likert 3-5) and Negative Initial Biopsy. A Mini Systematic Review. Eur Urol. 2022;82(5):452-457. https:\/\/doi.org\/10.1016\/j.eururo.2022.07.025","journal-title":"A Mini Systematic Review. Eur Urol."},{"issue":"3","key":"1150_CR5","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1016\/j.eururo.2019.02.033","volume":"76","author":"B Turkbey","year":"2019","unstructured":"Turkbey B, Rosenkrantz AB, Haider MA, et al. Prostate imaging reporting and data system version 21: 2019 update of prostate imaging reporting and data system version 2. Eur Urol. 2019;76(3):340\u2013351. https:\/\/doi.org\/10.1016\/j.eururo.2019.02.033","journal-title":"Eur Urol."},{"issue":"2","key":"1150_CR6","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1002\/jmri.28061","volume":"56","author":"M Klingebiel","year":"2022","unstructured":"Klingebiel M, Schimm\u00f6ller L, Weiland E, et al. Value of T2 mapping MRI for prostate cancer detection and classification. J Magn Reson Imaging. 2022;56(2):413-422. https:\/\/doi.org\/10.1002\/jmri.28061","journal-title":"J Magn Reson Imaging."},{"issue":"6","key":"1150_CR7","doi-asserted-by":"publisher","first-page":"1455","DOI":"10.1007\/s00345-022-03991-8","volume":"40","author":"T Hepp","year":"2022","unstructured":"Hepp T, Kalmbach L, Kolb M, et al. T2 mapping for the characterization of prostate lesions. World J Urol. 2022;40(6):1455-1461. https:\/\/doi.org\/10.1007\/s00345-022-03991-8","journal-title":"World J Urol."},{"issue":"4","key":"1150_CR8","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1016\/j.diii.2014.11.016","volume":"96","author":"A Hoang Dinh","year":"2015","unstructured":"Hoang Dinh A, Souchon R, Melodelima C, et al. Characterization of prostate cancer using T2 mapping at 3T: a multi-scanner study. Diagn Interv Imaging. 2015;96(4):365-372. https:\/\/doi.org\/10.1016\/j.diii.2014.11.016","journal-title":"Diagn Interv Imaging."},{"issue":"2","key":"1150_CR9","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1002\/jmri.25972","volume":"48","author":"T Hilbert","year":"2018","unstructured":"Hilbert T, Sumpf TJ, Weiland E, et al. Accelerated T2 mapping combining parallel MRI and model-based reconstruction: GRAPPATINI. J Magn Reson Imaging. 2018;48(2):359-368. https:\/\/doi.org\/10.1002\/jmri.25972","journal-title":"J Magn Reson Imaging."},{"issue":"6","key":"1150_CR10","doi-asserted-by":"publisher","first-page":"1202","DOI":"10.1002\/mrm.10171","volume":"47","author":"MA Griswold","year":"2002","unstructured":"Griswold MA, Jakob PM, Heidemann RM, et al. Generalized autocalibrating partially parallel acquisitions (GRAPPA). Magn Reson Med. 2002;47(6):1202-1210. https:\/\/doi.org\/10.1002\/mrm.10171","journal-title":"Magn Reson Med."},{"issue":"3","key":"1150_CR11","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1148\/radiol.2019182843","volume":"293","author":"M Roux","year":"2019","unstructured":"Roux M, Hilbert T, Hussami M, Becce F, Kober T, Omoumi P. MRI T2 Mapping of the Knee Providing Synthetic Morphologic Images: Comparison to Conventional Turbo Spin-Echo MRI. Radiology. 2019;293(3):620-630. https:\/\/doi.org\/10.1148\/radiol.2019182843","journal-title":"Radiology."},{"issue":"4","key":"1150_CR12","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2023.e15064","volume":"9","author":"N Gruenebach","year":"2023","unstructured":"Gruenebach N, Abello Mercado MA, Grauhan NF, et al. Clinical feasibility and validation of the accelerated T2 mapping sequence GRAPPATINI in brain imaging. Heliyon. 2023;9(4):e15064. https:\/\/doi.org\/10.1016\/j.heliyon.2023.e15064","journal-title":"Heliyon."},{"issue":"6","key":"1150_CR13","doi-asserted-by":"publisher","first-page":"3590","DOI":"10.1007\/s00330-020-07538-6","volume":"31","author":"M Raudner","year":"2021","unstructured":"Raudner M, Schreiner MM, Hilbert T, et al. Clinical implementation of accelerated T2 mapping: Quantitative magnetic resonance imaging as a biomarker for annular tear and lumbar disc herniation. Eur Radiol. 2021;31(6):3590-3599. https:\/\/doi.org\/10.1007\/s00330-020-07538-6","journal-title":"Eur Radiol."},{"issue":"2","key":"1150_CR14","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1002\/jmri.26612","volume":"50","author":"N Vietti Violi","year":"2019","unstructured":"Vietti Violi N, Hilbert T, Bastiaansen JAM, et al. Patient respiratory-triggered quantitative T2 mapping in the pancreas. J Magn Reson Imaging. 2019;50(2):410-416. https:\/\/doi.org\/10.1002\/jmri.26612","journal-title":"J Magn Reson Imaging."},{"issue":"6","key":"1150_CR15","doi-asserted-by":"publisher","first-page":"1859","DOI":"10.1002\/jmri.27297","volume":"52","author":"S Li","year":"2020","unstructured":"Li S, Liu J, Zhang F, et al. Novel T2 mapping for evaluating cervical cancer features by providing quantitative T2 maps and synthetic morphologic images: A preliminary study. J Magn Reson Imaging. 2020;52(6):1859-1869. https:\/\/doi.org\/10.1002\/jmri.27297","journal-title":"J Magn Reson Imaging."},{"issue":"6","key":"1150_CR16","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1097\/RLI.0000000000000852","volume":"57","author":"R Draveny","year":"2022","unstructured":"Draveny R, Ambarki K, Han F, et al. Comparison of T2 Quantification Strategies in the Abdominal-Pelvic Region for Clinical Use. Invest Radiol. 2022;57(6):412-421. https:\/\/doi.org\/10.1097\/RLI.0000000000000852","journal-title":"Invest Radiol."},{"key":"1150_CR17","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.684144","volume":"11","author":"M Wenzel","year":"2021","unstructured":"Wenzel M, von Hardenberg J, Welte MN, et al. Monoprophylaxis With Cephalosporins for Transrectal Prostate Biopsy After the Fluoroquinolone-Era: A Multi-Institutional Comparison of Severe Infectious Complications. Front Oncol. 2021;11:684144. https:\/\/doi.org\/10.3389\/fonc.2021.684144","journal-title":"Front Oncol."},{"key":"1150_CR18","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3389\/fsurg.2020.00007","volume":"7","author":"M Wenzel","year":"2020","unstructured":"Wenzel M, Theissen L, Preisser F, et al. Complication Rates After TRUS Guided Transrectal Systematic and MRI-Targeted Prostate Biopsies in a High-Risk Region for Antibiotic Resistances. Front Surg. 2020;7:7. https:\/\/doi.org\/10.3389\/fsurg.2020.00007","journal-title":"Front Surg."},{"issue":"5","key":"1150_CR19","doi-asserted-by":"publisher","first-page":"980","DOI":"10.1016\/j.euf.2020.11.006","volume":"7","author":"M Wenzel","year":"2021","unstructured":"Wenzel M, Welte MN, Theissen LH, et al. Comparison of Complication Rates with Antibiotic Prophylaxis with Cefpodoxime Versus Fluoroquinolones After Transrectal Prostate Biopsy. Eur Urol Focus. 2021;7(5):980-986. https:\/\/doi.org\/10.1016\/j.euf.2020.11.006","journal-title":"Eur Urol Focus."},{"key":"1150_CR20","doi-asserted-by":"publisher","unstructured":"Wenzel M, Preisser F, Wittler C, et al. Correlation of MRI-Lesion Targeted Biopsy vs. Systematic Biopsy Gleason Score with Final Pathological Gleason Score after Radical Prostatectomy. Diagnostics (Basel). 2021;11(5). https:\/\/doi.org\/10.3390\/diagnostics11050882","DOI":"10.3390\/diagnostics11050882"},{"key":"1150_CR21","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.1200\/CCI.20.00045","volume":"4","author":"J Scherer","year":"2020","unstructured":"Scherer J, Nolden M, Kleesiek J, et al. Joint imaging platform for federated clinical data analytics. JCO Clin Cancer Inform. 2020;4:1027-1038. https:\/\/doi.org\/10.1200\/CCI.20.00045","journal-title":"JCO Clin Cancer Inform."},{"issue":"3","key":"1150_CR22","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1016\/j.ejrad.2010.12.076","volume":"81","author":"O Ruprecht","year":"2012","unstructured":"Ruprecht O, Weisser P, Bodelle B, Ackermann H, Vogl TJ. MRI of the prostate: interobserver agreement compared with histopathologic outcome after radical prostatectomy. Eur J Radiol. 2012;81(3):456-460. https:\/\/doi.org\/10.1016\/j.ejrad.2010.12.076","journal-title":"Eur J Radiol."},{"issue":"1","key":"1150_CR23","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1007\/s00261-014-0197-7","volume":"40","author":"K Garcia-Reyes","year":"2015","unstructured":"Garcia-Reyes K, Passoni NM, Palmeri ML, et al. Detection of prostate cancer with multiparametric MRI (mpMRI): effect of dedicated reader education on accuracy and confidence of index and anterior cancer diagnosis. Abdom Imaging. 2015;40(1):134-142. https:\/\/doi.org\/10.1007\/s00261-014-0197-7","journal-title":"Abdom Imaging."},{"issue":"5","key":"1150_CR24","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1016\/j.mri.2015.02.006","volume":"33","author":"FI Yamauchi","year":"2015","unstructured":"Yamauchi FI, Penzkofer T, Fedorov A, et al. Prostate cancer discrimination in the peripheral zone with a reduced field-of-view T(2)-mapping MRI sequence. Magn Reson Imaging. 2015;33(5):525-530. https:\/\/doi.org\/10.1016\/j.mri.2015.02.006","journal-title":"Magn Reson Imaging."},{"issue":"5","key":"1150_CR25","doi-asserted-by":"publisher","first-page":"1400","DOI":"10.1002\/mrm.22874","volume":"65","author":"W Liu","year":"2011","unstructured":"Liu W, Turkbey B, S\u00e9n\u00e9gas J, et al. Accelerated T2 mapping for characterization of prostate cancer. Magn Reson Med. 2011;65(5):1400-1406. https:\/\/doi.org\/10.1002\/mrm.22874","journal-title":"Magn Reson Med."},{"issue":"5","key":"1150_CR26","doi-asserted-by":"publisher","first-page":"1928","DOI":"10.1177\/0300060517721071","volume":"46","author":"L Liu","year":"2018","unstructured":"Liu L, Yin B, Shek K, et al. Role of quantitative analysis of T2 relaxation time in differentiating benign from malignant breast lesions. J Int Med Res. 2018;46(5):1928-1935. https:\/\/doi.org\/10.1177\/0300060517721071","journal-title":"J Int Med Res."},{"issue":"1","key":"1150_CR27","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1177\/0284185116633916","volume":"58","author":"L-M Wu","year":"2017","unstructured":"Wu L-M, Yao Q-Y, Zhu J, et al. T2* mapping combined with conventional T2-weighted image for prostate cancer detection at 30T MRI: a multi-observer study. Acta Radiol. 2017;58(1):114\u2013120. https:\/\/doi.org\/10.1177\/0284185116633916","journal-title":"Acta Radiol."},{"issue":"3","key":"1150_CR28","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1148\/radiol.2019181705","volume":"292","author":"A Panda","year":"2019","unstructured":"Panda A, Obmann VC, Lo W-C, et al. MR fingerprinting and ADC mapping for characterization of lesions in the transition zone of the prostate gland. Radiology. 2019;292(3):685-694. https:\/\/doi.org\/10.1148\/radiol.2019181705","journal-title":"Radiology."}],"container-title":["Journal of Imaging Informatics in Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10278-024-01150-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10278-024-01150-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10278-024-01150-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,2]],"date-time":"2024-12-02T19:07:39Z","timestamp":1733166459000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10278-024-01150-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,26]]},"references-count":28,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["1150"],"URL":"https:\/\/doi.org\/10.1007\/s10278-024-01150-6","relation":{},"ISSN":["2948-2933"],"issn-type":[{"value":"2948-2933","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6,26]]},"assertion":[{"value":"16 November 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 May 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 May 2024","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 June 2024","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"For this IRB approved (No. 19-299), retrospective case-control study, the hospital's PACS was searched by an independent investigator for prostate MRIs between 08\/2018 and 07\/2019.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"For the retrospective case-control study, no consent to participate was needed.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"For the anonymized data, no consent to publish is needed.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Publish"}},{"value":"R.S. and T.H. are employed by Siemens Healthineers.\u00a0T.P. receives funding from Berlin Institute of Health (Advanced Clinician Scientist Grant, Platform Grant), Ministry of Education and Research (BMBF, 01KX2021 (RACOON), 01KX2121 (\u201eNUM 2.0\u201c, RACOON), 68GX21001A, 01ZZ2315D), German Research Foundation (DFG, SFB 1340\/2), European Union (H2020, CHAIMELEON: 952172, DIGITAL, EUCAIM:101100633) and reports research agreements (no personal payments, outside of submitted work) with AGO, Aprea AB, ARCAGY-GINECO, Astellas Pharma Global Inc. (APGD), Astra Zeneca, Clovis Oncology, Inc., Holaira, Incyte Corporation, Karyopharm, Lion Biotechnologies, Inc., MedImmune, Merck Sharp & Dohme Corp, Millennium Pharmaceuticals, Inc., Morphotec Inc., NovoCure Ltd., PharmaMar S.A. and PharmaMar USA, Inc., Roche, Siemens Healthineers, and TESARO Inc., and fees for a book translation (Elsevier B.V.).\u00a0A.M.B.: Bayer, Guebert, Siemens Healthineers (Consulting fees and travel Support).","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}]}}